Kowa Pharmaceutical Europe

Kowa Pharmaceutical Europe is the European subsidiary of the Japanese multinational Kowa Company, Ltd., specializing in the development and commercialization of therapies for cardiometabolic diseases. The company's primary focus is on the management of dyslipidemia and cardiovascular risk, highlighted by its flagship product Livalo (pitavastatin), a potent HMG-CoA reductase inhibitor. Kowa is also advancing pemafibrate, a selective peroxisome proliferator-activated receptor alpha (SPPARM-alpha) modulator, aimed at treating hypertriglyceridemia. Headquartered in the United Kingdom with additional operations in Germany, the company manages clinical trials, regulatory affairs, and marketing strategies across the European region. Kowa Pharmaceutical Europe leverages the extensive research and manufacturing capabilities of its parent organization to bring specialized treatments to the European healthcare market.